Literature DB >> 2539214

Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia.

W Digel1, M Stefanic, W Schöniger, C Buck, A Raghavachar, N Frickhofen, H Heimpel, F Porzsolt.   

Abstract

The biologic effects of recombinant tumor necrosis factor-alpha (rTNF-alpha) and the expression of specific TNF membrane receptors on isolated neoplastic B cells from previously untreated patients with chronic lymphocytic leukemia (CLL) were investigated in vitro. Isolated B cells were incubated up to six days with various concentrations of rTNF-alpha (0.1 to 100 ng/mL). B cells from most patients proliferated ranged from two to 104 times that of unstimulated cells from the same patients. An optimal proliferative effect was achieved at 25 ng/mL rTNF-alpha and an incubation time between 96 and 120 hours, whereas a low concentration of rTNF-alpha (1 ng/mL) reduced [3H]TdR incorporation in four cases. Metaphase cells were detected in the rTNF-alpha-stimulated cultures that proliferated in response to rTNF-alpha. B cells from three of ten patients proliferated spontaneously and proliferation was further enhanced in two patients by rTNF-alpha. TNF binding assays gave a value of approximately 390 to 1,400 binding sites/cell for TNF and a dissociation constant (kd) of approximately 60 pmol/L. These data indicate that rTNF-alpha, in contrast to its cytotoxic/cytostatic effects, can also induce proliferation of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539214

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

2.  The diverse roles of the TNF axis in cancer progression and metastasis.

Authors:  Boram Ham; Maria Celia Fernandez; Zarina D'Costa; Pnina Brodt
Journal:  Trends Cancer Res       Date:  2016-01-01

3.  Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Thomas J Kipps; Ian W Flinn; Maureen Cooper; Olatoyosi Odenike; Jennifer Bendiske; John Rediske; Sanela Bilic; Jyotirmoy Dey; Johan Baeck; Susan O'Brien
Journal:  Leuk Lymphoma       Date:  2012-06-12

4.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

5.  IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells.

Authors:  Lin Gui; Qingyu Zeng; Zhigang Xu; Hai Zhang; Shanshan Qin; Chunxiao Liu; Chong Xu; Zhou Qian; Shuangquan Zhang; Shile Huang; Long Chen
Journal:  Cytokine       Date:  2016-05-25       Impact factor: 3.861

6.  Gene expression of cytokines suppressing hematopoietic progenitor cells in lymphoid malignancies.

Authors:  C Kawasaki; S Okamura; S Hayashi; S Kondo; M Harada; Y Niho
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Tumor necrosis factor downregulates granulocyte-colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes.

Authors:  O Elbaz; L M Budel; H Hoogerbrugge; I P Touw; R Delwel; L A Mahmoud; B Löwenberg
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

Authors:  D Aderka; H Engelmann; Y Maor; C Brakebusch; D Wallach
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

9.  High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

Authors:  W Digel; F Porzsolt; M Schmid; F Herrmann; W Lesslauer; M Brockhaus
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

10.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.